Peply
← All Compounds

Inclusion of a compound does not constitute endorsement. Information sourced from published research and regulatory filings.

CJC-1295 (with DAC)

Cat 2 → Pending Cat 1

GH Secretagogue · Research peptide (multiple suppliers)

GHRH analog with a Drug Affinity Complex (DAC) that extends its half-life by binding to albumin, producing sustained elevated GH and IGF-1 levels.

About

Mechanism
GHRH analog with a Drug Affinity Complex (DAC) that extends its half-life by binding to albumin. Produces sustained, elevated GH and IGF-1 levels rather than pulsatile release.
Half-Life
Approximately 8 days (due to DAC albumin binding)
Route
subcutaneous
Frequency
Once weekly

Clinical Dosing

1-2 mgonce weekly

Not FDA-approved. Currently Category 2 (restricted). Pending return to Category 1. The DAC variant produces sustained (non-pulsatile) GH elevation.

Dosing based on small human studies or early-phase trials. Not established by Phase 3 evidence.

Regulatory Status

FDA Category
Research peptide (FDA Category 2)
Reclassification
pending
Date Restricted
2023-09-29
Announced Return
2026-02-27

Status based on publicly available FDA communications. Verify at FDA.gov for authoritative guidance.

View full regulatory timeline →

Titration Protocols

Research Protocol

Source: Teichman et al., Journal of Clinical Endocrinology & Metabolism, 2006

DoseDurationDraw (2 mg vial in 2mL)Notes
2 mgMaintenance2.00 mL (200 units)Standard weekly dose

Available Vial Sizes

2 mg

2 mg vial

5 mg

5 mg vial

Citations

  1. [1]Prolonged Stimulation of Growth Hormone and IGF-I After Single Subcutaneous Administration of CJC-1295. Journal of Clinical Endocrinology & Metabolism, 91(3), 799-805. Link(Reviewed: 2026-02-27)